175 related articles for article (PubMed ID: 27647223)
1. Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.
Cazzaniga ME; Torri V; Riva F; Porcu L; Cicchiello F; Capici S; Cortinovis D; Digiacomo N; Bidoli P
Tumori; 2017 Jan; 103(1):e4-e8. PubMed ID: 27647223
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Montagna E; Palazzo A; Maisonneuve P; Cancello G; Iorfida M; Sciandivasci A; Esposito A; Cardillo A; Mazza M; Munzone E; Lai A; Goldhirsch A; Colleoni M
Cancer Lett; 2017 Aug; 400():276-281. PubMed ID: 28131905
[TBL] [Abstract][Full Text] [Related]
4. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer.
Di Seri M; De Sanctis R; Quadrini S; Adua D; Stumbo L; Del Signore E; Gori B; Grassi P; Basile ML; Longo F
J Chemother; 2011 Apr; 23(2):110-3. PubMed ID: 21571629
[TBL] [Abstract][Full Text] [Related]
8. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
9. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Tawfik H; Rostom Y; Elghazaly H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
[TBL] [Abstract][Full Text] [Related]
10. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
[TBL] [Abstract][Full Text] [Related]
13. Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Palomo AG; Glogowska I; Sommer H; Malamos N; Kilar E; Vega JM; Torrecillas L; Delozier T; Ettl J; Finek J
Anticancer Res; 2012 Oct; 32(10):4539-45. PubMed ID: 23060583
[TBL] [Abstract][Full Text] [Related]
14. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines.
Campone M; Dobrovolskaya N; Tjulandin S; Chen SC; Fourie S; Mefti F; Konstantinova M; Lefresne F; Meheust N; Jassem J
Breast J; 2013; 19(3):240-9. PubMed ID: 23528159
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Hess D; Koberle D; Thurlimann B; Pagani O; Schonenberger A; Mattmann S; Rochlitz C; Rauch D; Schuller JC; Ballabeni P; Ribi K;
Oncology; 2007; 73(3-4):228-37. PubMed ID: 18424887
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.
Chai Y; Liu J; Jiang M; He M; Wang Z; Ma F; Wang J; Yuan P; Luo Y; Xu B; Li Q
Thorac Cancer; 2023 Aug; 14(23):2259-2268. PubMed ID: 37402471
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
Nolè F; Catania C; Munzone E; Rocca A; Verri E; Sanna G; Ascione G; Adamoli L; Zampino MG; Minchella I; Goldhirsch A
Clin Breast Cancer; 2006 Feb; 6(6):518-24. PubMed ID: 16595035
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
Finek J; Holubec L; Svoboda T; Sefrhansova L; Pavlikova I; Votavova M; Sediva M; Filip S; Kozevnikova R; Kormunda S
Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
[TBL] [Abstract][Full Text] [Related]
19. Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer.
Brems-Eskildsen AS; Linnet S; Danø H; Luczak A; Vestlev PM; Jakobsen EH; Neimann J; Jensen CB; Dongsgaard T; Langkjer ST
Acta Oncol; 2021 Feb; 60(2):157-164. PubMed ID: 33259244
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
